Provider review
Longevixx Review: The Same Nineteen Peptides as Alinwell, With Nothing to Check Them Against
Longevixx's nineteen peptide cards are the same nineteen cards Alinwell publishes — same names, same prices, same descriptions, same heading, compared line by line on 1 September 2026. Where the two part company is everything a buyer would use to check them. Alinwell links seventeen certificates of analysis; Longevixx links none. Alinwell's certificates name the laboratory and the compounder; Longevixx names no pharmacy anywhere on its site, and never uses the words 503A or 503B at all. It also has no refund policy.
The same nineteen peptides Alinwell sells, at the same prices, described in the same words — with no certificate, no named pharmacy and no refund policy behind any of them.
Worth trusting if
- You have already decided on a molecule and are buying on price alone
- You want tesamorelin or PT-141, the two products here with completed phase 3 trials
- You are comfortable with a company that names no pharmacy and publishes no test result
Be skeptical if
- You want to read a certificate of analysis, because this site publishes none
- You want to know who compounds your prescription, which it never says
- You want a refund route in writing, because this company publishes none
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens startlongevix.com. A link is not a recommendation to take anything.
Provenance
What Longevixx actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin — $249/mo, quoted as a floor rather than a rate.
- NAD+ Injection — $199/mo, the cheapest program Longevixx sells.
- MOTS-C — $279/mo.
- Tesamorelin — $299/mo alone, or $349 paired with ipamorelin, where the pair carries this same sentence.
- BPC-157 — $250/mo alone. Five further products contain it, from $199 to $379.
- GHK-Cu — $249/mo. This same sentence is printed on two blends that are mostly other peptides.
- Epithalon — $249/mo alone, or $319 paired with GHK-Cu, where the pair carries this sentence.
- Thymosin A-1 — $299/mo, the only product in Longevixx's immune category.
- DSIP — $249/mo. A three-peptide blend at $329 carries this same sentence.
- Semax / Selank — $299/mo, sold as a pair rather than separately.
- PT-141 — $249/mo, the only product in Longevixx's sexual-health category.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
6
Molecules with human evidence
For the use they are sold for, out of 11 products reviewed here. The evidence belongs to the molecule, not to Longevixx.
8
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Longevixx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
SermorelinSermorelin · Compounded (503A)Claim reaches past the trials
“A growth-hormone-releasing hormone used to support natural GH production, recovery, and sleep.”
Read on the Longevixx site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests recovery or sleep quality as an outcome in healthy adults. A parallel ClinicalTrials.gov search for sermorelin as an intervention returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
One of the three outcomes named here has a literature behind it. Sermorelin raises growth hormone, which is what all 19 randomized trials measured. Recovery and sleep were never an outcome in any of them. A buyer has no way to tell which third of the sentence is the tested part, and on this site no certificate exists to tell them what is in the vial either.1
NAD+ InjectionNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“A cellular coenzyme used to support energy, mental clarity, and healthy aging.”
Read on the Longevixx site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
Energy, mental clarity and healthy aging are precisely the outcomes an injected NAD+ trial would need to measure, and none has reported. The literature usually offered in support is about oral precursors, which are different molecules taken a different way. This is the cheapest product on the menu and the one with the least behind it.2
MOTS-CMOTS-c · Compounded (503A)No trial supports this claim
“A mitochondrial-derived peptide used to support cellular energy, metabolism, and exercise capacity.”
Read on the Longevixx site, September 2026
Phase 2 only
- NCT07505745 MOTS-MET — Phase 2, recruiting, n=120. Recruiting, not reporting. No completed human efficacy result exists for a metabolic outcome.
The right trial is running and has not finished. MOTS-MET is recruiting 120 participants for a metabolic outcome; until it reports there is nothing for a claim about energy, metabolism or exercise capacity to rest on. An unfinished literature is not the same as a hostile one, and it is not the same as support either.3
TesamorelinTesamorelin · Compounded (503A)Claim reaches past the trials
“A growth-hormone-releasing analog used to support fat metabolism and healthy body composition.”
Read on the Longevixx site, September 2026
Phase 3 trials
What the trials show for Tesamorelin
- NCT00123253 — Phase 3, completed, n=412. The pivotal trial of tesamorelin in HIV patients with excess abdominal fat. The outcome measured was visceral abdominal fat, in that population.
- NCT00608023 — Phase 3, completed, n=263. The extension study in the same HIV-associated lipodystrophy population.
This is the best-evidenced molecule on the menu and its evidence is about someone else. Two completed phase 3 trials, 675 participants, studying visceral fat in HIV-associated lipodystrophy — a disfiguring condition with a specific pathology. Extending that to "healthy body composition" in a general adult is the extrapolation the card makes silently.4,5
BPC-157BPC-157 · Compounded (503A)No trial supports this claim
“Body Protection Compound — used to support tissue repair, gut health, and recovery.”
Read on the Longevixx site, September 2026
Phase 1 only
What the trials show for BPC-157
- NCT02637284 — Phase 1, unknown status, n=42. The registry record for BPC-157 in humans sits at phase 1 — tolerability, not effect — and its status is unknown rather than completed.
Phase 1 establishes whether a dose is tolerated. It does not measure tissue repair, gut symptoms or recovery time, which is everything this sentence promises. The registry does not even record the study as completed — its status is unknown. Longevixx sells six products containing this molecule and publishes no test result for any of them.6
GHK-CuGHK-Cu · Compounded (503A)Claim reaches past the trials
“A copper peptide used to support skin, collagen, hair, and tissue regeneration.”
Read on the Longevixx site, September 2026
Phase 2 only
What the trials show for GHK-Cu
- NCT07437586 — Phase 2, recruiting, n=60. Acute skin wound healing, recruiting. The completed GHK-Cu registry record is a 27-participant study of facial skin quality; neither studies hair.
Skin, collagen and tissue are the outcomes the GHK-Cu literature is about, thinly. Hair is not studied in any GHK-Cu record in the registry, in any formulation, and it is the word most likely to sell a copper peptide to someone worried about losing theirs.7
EpithalonEpithalon (epitalon) · Compounded (503A)No trial supports this claim
“A peptide studied for supporting cellular longevity, sleep quality, and healthy aging.”
Read on the Longevixx site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search returned zero studies for "Epithalon", zero for the spelling "Epitalon" and zero for "Epithalamin" — no registered trial of this molecule exists anywhere in the registry, for any indication, under any spelling. In PubMed, a search restricted to the randomized-controlled-trial publication type returns zero records. The randomized literature a looser search surfaces tests EPITHALAMIN, a peptide extract of bovine pineal gland rather than the synthetic tetrapeptide, and comes from a single research group.
"Studied for" is the most carefully chosen phrase on this page. Epithalon has no registered trial anywhere in the world under any of its three spellings and no randomized-controlled-trial record in PubMed. The work usually cited is on epithalamin, a bovine pineal extract — a different substance, not an earlier version of this one.8
Thymosin A-1Thymosin alpha-1 · Compounded (503A)Claim reaches past the trials
“An immune-modulating peptide used to support immune resilience and balance.”
Read on the Longevixx site, September 2026
Phase 3 trials
- NCT02867267 TESTS — Phase 3, completed, n=1,106. Thymosin alpha-1 in SEPSIS — completed phase 3, 1,106 critically ill patients. The strongest evidence this molecule has, in a population nobody joins voluntarily.
Searched live on 2026-09-01, thymosin alpha-1 has 64 randomized-trial records in PubMed and 64 registered studies — genuinely substantial, and read rather than counted they are hepatitis B, sepsis, severe pancreatitis, cirrhosis and cancer immunotherapy. Modulating immunity in a patient in intensive care is a different claim from supporting "resilience and balance" in a well adult, and only the first has been tested.9
DSIPDSIP (delta sleep-inducing peptide) · Compounded (503A)Claim reaches past the trials
“Delta sleep-inducing peptide used to support deep, restorative sleep.”
Read on the Longevixx site, September 2026
No trial for this use
Searched live on 2026-09-01. The same searches were run for tirzepatide in the same pass to confirm they were working, and returned 2,451 PubMed records, 134 randomized-trial records and 278 registry studies. DSIP returns 544 PubMed records, 7 carrying the randomized-controlled-trial publication type, and ZERO registry studies — the single registry hit is an L-carnitine study that does not involve DSIP. Reading the 7 rather than counting them: two are false positives, including a cervical-spine screw-fixation trial where DSIP is an unrelated abbreviation. The genuine sleep trials are two, published in 1981 and 1992, both in patients with chronic insomnia. Nothing tests sleep quality in adults without a sleep disorder.
Two randomized sleep trials exist, from 1981 and 1992, and both enrolled people with chronic insomnia. That is more than most of this menu can show and it is not what is being sold: nothing has tested deep or restorative sleep in adults who already sleep normally, and no registered trial of the molecule exists today. The most recent randomized sleep record is 34 years old.10
Semax / SelankSemax and Selank · Compounded (503A)No trial supports this claim
“Nootropic peptides used to support focus, mood, and cognitive resilience.”
Read on the Longevixx site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search returns zero records naming Semax and zero naming Selank. The published literature is not empty and the distinction matters: PubMed holds 207 records mentioning Semax, of which one carries the randomized-controlled-trial publication type — a 2007 Russian-language paper on motor neuron disease, not attention or cognition. It holds 68 mentioning Selank, of which two are randomized trials, both in the same Russian journal and both in anxiety disorders.
Three randomized trials exist across the two molecules and not one is about focus or cognition in a healthy person — Semax's single record is in motor neuron disease, Selank's two are in anxiety disorders. Neither molecule has a registered trial anywhere. "Nootropic" is a category label being asked to do the work of a finding.11
PT-141Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“A peptide used to support libido and sexual arousal in men and women.”
Read on the Longevixx site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
The women's half of this sentence rests on 1,437 participants across two phase 3 trials, which is why an approved product exists. The men's half rests on nothing in that record — the RECONNECT trials enrolled premenopausal women with hypoactive sexual desire disorder and nobody else. Longevixx also never mentions that an approved version of this molecule is on the market.12
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere on this site, and the census that establishes it is dated rather than impressionistic. On 2026-09-01 the visible text and DOM of the homepage, the terms, privacy and HIPAA pages, the about and contact pages, the peptides page, all three treatment pages and all 25 intake screens were searched for "pharmacy", "pharmacies", "503A", "503B", "compounded by", "", "medical group", "dba", "PLLC" and "P.C." The result was zero on every term — the only "dba" hit sat inside the word "feedback". The nearest thing to a disclosure is the site-wide disclaimer, which says practitioners "may prescribe custom-compounded formulations prepared by licensed pharmacies", naming none of them. No prescriber, medical group or telehealth platform is named either; the intake and checkout run on the brand's own application.
Read on the Longevixx site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Nothing. A census of the peptides page on 2026-09-01 returns zero occurrences of "certificate of analysis" or "COA" in the visible text, and no potency, purity or sterility result appears anywhere on the site. That absence is worth more than usual here because the comparison is available: the identical menu at Alinwell links seventeen certificates, naming both the laboratory and the compounding pharmacy. Same nineteen products, same nineteen prices, same nineteen sentences — and on this site there is nothing to open.
Licensing
Licensed to dispense, and where
Coverage
Longevixx says three ways on its marketing pages that it covers 50 states — a homepage ticker, a stat block and a badge strip — and its intake's shipping selector offers 51 options once the District of Columbia is counted. Its own contact page says something narrower: "Longevixx operates via telehealth in the states where it is licensed", and a treatment FAQ repeats it as "across the states where we're available". No exclusion list is published either way.
Read the full licensing claim
"Reviewed by a licensed provider" and "Compounded in a U.S. pharmacy" on each of the nineteen peptide cards, with no license number, prescriber or medical group published anywhere on the domain.
Read on the Longevixx site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- The whole nineteen-program menu is priced on a public page before any questionnaire — its GLP-1 line, by contrast, shows no price until twenty-five screens in.
- Its disclaimer states plainly that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA.
- It does not claim testing it cannot show. Several sellers assert third-party testing with nothing behind it; Longevixx makes no testing claim at all, which is at least consistent.
Show 3 more
- Tesamorelin and PT-141 are real molecules with completed phase 3 trials, and the tesamorelin card describes the mechanism accurately even where it overreaches on the population.
- Every card states that a licensed provider reviews the request, so nothing is presented as available without a prescription.
- No FDA warning letter for the company under any spelling of its name.
- No certificate of analysis exists anywhere on the site — no potency, purity or sterility result for any of the nineteen products.
- No pharmacy is named. A census across ten pages and all 25 intake screens returned zero occurrences of "pharmacy", "503A" or "503B".
- No prescriber or medical group is named either, on a site selling eleven prescription-only molecules.
Show 6 more
- There is no refund policy. No refunds page exists, and the only refund sentence in the terms covers a pricing error Longevixx itself makes.
- "$0 if you're not approved" is promised repeatedly on the homepage and appears in no clause of the terms.
- Eight of nineteen cards carry a description belonging to one ingredient — a four-peptide blend is introduced as "a copper peptide", and ipamorelin is never described at all.
- Nine of the eleven molecules we graded claim more than their trials show, and three of them have no registered trial anywhere in the world.
- "Telehealth in 50 states" on the marketing pages against "in the states where it is licensed" on its own contact page, with no exclusion list to reconcile them.
- Its patient counts and ratings disagree across the site — 1,743+ and 7,200+ patients, and 4.8, 4.9 and 4.98 ratings, with no review platform named for any of them.
Verdict
The bottom line
If you are going to buy this menu, buy it from the storefront that will show you a lab result. The products, the prices and the descriptions here are identical to Alinwell's down to the heading, so the only thing that distinguishes the two is what each will let you check — and this one publishes no certificate, names no pharmacy and offers no refund route. On the evidence itself, tesamorelin and PT-141 are the only two products with completed phase 3 trials, and both were tested in populations you are unlikely to be in.
Opens startlongevix.com. A link is not a recommendation to take anything.
The comparison that decides this review
Longevixx's peptide page and Alinwell's peptide page were read with the same tool on 1 September 2026 and compared card by card, as (name, price, description) triples.
Nineteen of nineteen matched. Same product names. Same prices, to the dollar. Same descriptions, word for word. Same heading — "Precision peptides, guided by your goal."
Longevixx LLC is registered in Charlotte, North Carolina. Alinwell LLC is in Southlake, Texas. Neither site mentions the other anywhere.
That points to a shared vendor or platform. It is not evidence of common ownership and we are not claiming any. What makes it worth reporting is that it isolates the variable: when two storefronts are identical, the difference between them is the whole story.
Here is the difference. Alinwell links seventeen certificates of analysis, naming Miraxis Labs in San Diego as the testing laboratory and Greenwich Rx as the compounder. Longevixx links none. A census of its peptides page returns zero occurrences of "certificate of analysis" or "COA" in the visible text.
Full analysis — 4 more sectionsWhat is not published · The descriptions belong to the wrong products · What the trials show · What this means if you are buying
What is not published
No pharmacy. No laboratory. No prescriber. No medical group.. No compounding class.
That last one is not an oversight so much as a vocabulary gap: a census across the homepage, terms, privacy, HIPAA, about, contact and peptides pages, all three treatment pages and all 25 intake screens found zero occurrences of "503A", "503B", "pharmacy" or "pharmacies". The only "dba" hit was inside the word "feedback".
The nearest thing to a supply-chain statement is the site-wide disclaimer:
"practitioners may prescribe custom-compounded formulations prepared by licensed pharmacies"
Which pharmacies is not answered anywhere.
There is also no refund policy. No refunds page exists. The single refund sentence in the terms covers a pricing error Longevixx itself makes — and the homepage promises "$0 if you're not approved" in words that appear in no clause of the contract.
The descriptions belong to the wrong products
Eight of the nineteen programs are blends, and every blend inherits a description from one ingredient.
| Program | The sentence printed under it | Whose it is | |---|---|---| | BPC-157 / GHK-Cu / KPV / TB500 — $379 | "A copper peptide used to support skin, collagen, hair…" | GHK-Cu's | | BPC-157 / TB-500 / GHK-Cu — $349 | the same copper-peptide sentence | GHK-Cu's | | GHK-Cu / Epithalon — $319 | "A peptide studied for supporting cellular longevity…" | Epithalon's | | Tesamorelin / Ipamorelin — $349 | "A growth-hormone-releasing analog…" | Tesamorelin's | | BPC-157 / TB500 — $299 | "Body Protection Compound…" | BPC-157's | | BPC-157 / KPV / TB500 — $329 | the same BPC-157 sentence | BPC-157's | | BPC-157 Acetate — $199 | the same BPC-157 sentence | BPC-157's | | DSIP / BPC / CJC — $329 | "Delta sleep-inducing peptide…" | DSIP's |
A four-peptide product at $379 a month is introduced to the buyer as "a copper peptide". Ipamorelin is never described anywhere on the site. Neither is KPV, which appears only inside two blends named after something else.
What the trials show
Of the eleven single molecules graded here, two have completed phase 3 trials, two have a trial still recruiting, one sits at phase 1, and four have no registered trial anywhere in the world.
Tesamorelin — two completed phase 3 trials, 675 participants, studying visceral fat in HIV-associated lipodystrophy. 4 Sold here for "healthy body composition".
PT-141 — RECONNECT 1 and 2, 1,437 premenopausal women with hypoactive sexual desire disorder, the basis of an FDA approval. 12 Sold here "in men and women".
Thymosin alpha-1 — 64 randomized-trial records and 64 registered studies, all of them in hepatitis, sepsis, pancreatitis, cirrhosis or oncology, including a completed phase 3 trial in 1,106 septic patients. 9 Sold here for "immune resilience and balance".
Sermorelin — 19 randomized trials, newest from 2005, every one measuring growth hormone secretion or growth in children. 1 Sold here for "GH production, recovery, and sleep". The first of those three is the tested one.
Epithalon — no registered trial anywhere, under any of three spellings, and no randomized-controlled-trial record in PubMed. 8 The literature cited in its defense is about epithalamin, a bovine pineal extract, which is a different substance.
DSIP — searched live, with tirzepatide run through the same filters in the same pass to confirm the searches work. DSIP returned 544 PubMed records, seven of the randomized-trial type, and zero registered studies. Two of the seven are false positives. The genuine sleep trials are two, from 1981 and 1992, both in chronic insomnia. 10
KPV, which appears in two blends, has no registered trial and no genuine randomized trial at all — both of its apparent hits are unrelated studies that matched on an abbreviation.
What this means if you are buying
The evidence problems here belong to the molecules and they are the same problems anywhere you buy them. The problems that belong to this seller are the ones about checking: nothing to read, nobody named, no way back if it goes wrong.
If this menu is what you want, the identical one next door will at least show you a certificate.
Questions
Frequently asked questions
Does Longevixx publish test results?
No. A census of its peptides page on 1 September 2026 found zero occurrences of "certificate of analysis" or "COA" in the visible text, and no potency, purity or sterility result appears anywhere on the site. The identical menu at Alinwell links seventeen certificates, so the absence here is a choice rather than a constraint of the category.
Which pharmacy compounds these peptides?
The site never says. A census across ten pages and all 25 intake screens returned zero occurrences of "pharmacy", "pharmacies", "503A" or "503B" — Longevixx does not use the compounding vocabulary at all. Its disclaimer refers only to "licensed pharmacies" in the plural and names none.
Why is this menu identical to Alinwell's?
We do not know, and we are careful about what that means. Comparing the two pages card by card, nineteen of nineteen match on name, price and description. The two companies are separate LLCs in different states and neither mentions the other. Identical storefront copy points to a shared vendor or platform; it is not evidence of common ownership.
Which of these actually has evidence behind it?
Tesamorelin and PT-141 have completed phase 3 trials, and thymosin alpha-1 has substantial phase 3 evidence in sepsis — but all three were tested in specific patient populations rather than in the general adults this menu addresses. The rest is at phase 1, still recruiting, or has no registered trial at all.
Can I get a refund if something goes wrong?
Nothing on the site says you can. There is no refunds page, and the only refund sentence in the terms covers Longevixx correcting its own pricing error. Its homepage promise of "$0 if you're not approved" is not restated in any clause, so it is marketing rather than a term you could hold the company to.
Glossary
Key terms
Show definitions
- Certificate of analysis
- A laboratory report for one manufactured lot, giving identity, potency and sterility results against a specification. Longevixx publishes none.
- 503A
- The section of the Food, Drug, and Cosmetic Act covering a preparation compounded by a state-licensed pharmacy against a prescription for one named patient. This term appears nowhere on Longevixx's site.
Compare
Others selling what Longevixx sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Longevixx's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 12 sources
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). MOTS-MET — MOTS-c registry record, phase 2, recruiting, NCT07505745. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07505745
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine 357(23):2359-70. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Theratechnologies (2026). TH9507 in Patients With HIV-Associated Lipodystrophy, NCT00123253 — phase 3, completed, enrolment 412; and TH9507 Extension Study, NCT00608023 — phase 3, completed, enrolment 263. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT00123253
- US National Library of Medicine (2026). BPC-157 — registry record, phase 1, status unknown, NCT02637284. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02637284
- US National Library of Medicine (2026). GHK-Cu — registry record, phase 2, recruiting, acute skin wound healing, NCT07437586; the completed GHK-Cu record is a 27-participant study of facial skin quality, and no registry record studies hair. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07437586
- US National Library of Medicine (2026). ClinicalTrials.gov intervention search: "Epithalon", "Epitalon" and "Epithalamin" — zero studies under any spelling; PubMed restricted to randomized controlled trial[pt] — zero records. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=Epithalon
- US National Library of Medicine (2026). TESTS — The Efficacy and Safety of Ta1 for Sepsis, NCT02867267, phase 3, completed, enrolment 1,106. Intervention search "thymalfasin OR thymosin alpha-1" returned 64 studies, in hepatitis, sepsis, pancreatitis, cirrhosis and oncology. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02867267
- US National Library of Medicine (2026). PubMed search: (delta sleep-inducing peptide OR DSIP) AND randomized controlled trial[pt] — 7 records, two of them false positives, the two genuine sleep trials published 1981 and 1992 in chronic insomnia; ClinicalTrials.gov intervention search — zero DSIP studies. The same searches run for tirzepatide in the same pass returned 134 randomized-trial records and 278 registry studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=%28delta+sleep-inducing+peptide+OR+DSIP%29+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov intervention search: zero records naming Semax and zero naming Selank. PubMed: 207 records mentioning Semax, one carrying the randomized-controlled-trial publication type (2007, motor neuron disease); 68 mentioning Selank, two randomized trials, both in anxiety disorders. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=Semax
- Kingsberg SA, Clayton AH, Portman D, Williams LA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology 134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.